Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403582 | 0.82 | GAA (0.56) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL29420085 | 0.78 | TSHR (0.70) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL827884 | 0.78 | TSHR (0.70) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL670777 | 0.76 | GAA (0.67) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL29402330 | 0.76 | GAA (0.67) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL6058773 | 0.76 | NOTUM (0.35) | GAATSHRGLAPOLBCFTR | |
| SCHEMBL109685 | 0.76 | TSHR (1.00) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL17451259 | 0.76 | TSHR (1.00) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL29350569 | 0.76 | TSHR (1.00) | GAATSHRGLAPOLBKIF11 | |
| SCHEMBL3533535 | 0.74 | TSHR (0.64) | GAATSHRGLAPOLBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2021-09-09 | — | — | US | disclosed |
| CN-108017557-B | Cyanidation method for preparing nitrile compound | 中国科学院兰州化学物理研究所苏州研究院 | 2020-11-24 | — | — | CN | disclosed |
| CN-111741754-A | Deuterated compounds as immunomodulators | 凯莫森特里克斯股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| EP-3703687-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | ChemoCentryx, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| CN-1152031-C | Isoquinoline derivatives having angiogenesis inhibitory activity | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-6608071-B2 | Angiogenesis inhibitors as antitumor agents | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
| US-20020010181-A1 | Isoquinoline derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2002-01-24 | — | — | US | disclosed |
| CN-1319100-A | Isoquinoline derivatives having angiogenesis inhibitory activity | NOVARTIS AG (CH) | 2001-10-24 | — | — | CN | disclosed |
| EP-1107964-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000009495-A1 | ISOQUINOLINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807609-B2 | Deuterated compounds as immunomodulators | C3AR1, C5AR1, C5AR2 | GAA 4867/4885TSHR 236/4885GLA 4000/4885 |
| US-20020010181-A1 | Isoquinoline derivatives with angiogenesis inhibiting activity | VEGFA, CCNY, PGF | GAA 4481/4885TSHR 2127/4885GLA 1967/4885 |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | BRAF, RAF1, NRAS | GAA 4834/4885TSHR 73/4885GLA 3973/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | GAA 4845/4885TSHR 52/4885GLA 3928/4885 |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | GAA 4867/4885TSHR 236/4885GLA 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.